Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
Iran's Revolutionary Guard says it seized a British tanker in the Strait of Hormuz, claiming it failed to follow international marine regulations.World Newsread more
More than a quarter of the S&P 500 companies report earnings in the week ahead, and that could buffet the market as investors await the Fed's meeting at the end of the month.Market Insiderread more
Walmart is making further organizational changes as it continues to integrate its store and digital operations and leadership, according to a memo obtained by CNBC that was...Retailread more
George Nader helped arrange a January 2017 meeting in the Seychelles between Erik Prince and the head of Russia's sovereign wealth fund, who reported directly to Vladimir...Politicsread more
These are the stocks posting the largest moves midday.Market Insiderread more
"I'm not hearing people blame the Fed as much as they're blaming tariffs," says CNBC's Jim Cramer.US Economyread more
Earlier, Williams said in a speech that "it's better to take preventative measures than to wait for disaster to unfold."The Fedread more
Four members of the House Armed Services Committee, including ranking member Rep. Mac Thornberry, R-Texas, said moving forward with the contract was critical to U.S. national...Technologyread more
Biogen stock rose 4.1 percent, while Ionis surged more than 30 percent.
The product, known as nusinersen, was developed by Biogen in collaboration with Ionis to treat spinal muscular atrophy, a genetic disease affecting the part of the nervous system that controls voluntary muscle movement. The disease can take away the ability to walk, eat, or breathe, and it is the leading cause of infant mortality, the companies said.
In the analysis, infants with SMA who got the drug achieved motor-skills development milestones better than those who didn't get the treatment, Biogen and Ionis said in a joint news release. The drug was also found to have an "acceptable" safety profile.
Based on the results, Biogen will stop the trial and all the patients will now receive the drug in a follow-on study, the companies said.
Biogen plans to develop and commercialize the drug globally. The company paid Ionis a $75 million licensing fee, and said it will, in the coming months, file to get the therapy approved by regulators.
Ionis is eligible to receive tiered royalties on any potential sales of nusinersen up to a certain percentage, and up to $150 million in milestone payments, according to Reuters.
"We remain committed to understanding the potential of nusinersen in the broader SMA population and will continue to focus on the rapid completion of our ongoing studies," B. Lynne Parshall, chief operating officer of Ionis, said in the same release.
Biogen's stock has dropped somewhat this year, falling more than 5 percent at one time.
BIIB 2016 Stock
Ionis' stock has plummeted so far in 2016, at one point down more than 52 percent.
IONS 2016 Stock